Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
Interpace Biosciences's gross margin for the twelve months ending Jun 30, 2026 was 63.7%. For fiscal 2025 it was 62.3%, against 63.8% the year before. The highest annual figure on record is 229.4% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.3% | −1.5 |
| FY2024 | Dec 31, 2024 | 63.8% | +1.2 |
| FY2023 | Dec 31, 2023 | 62.6% | +5.3 |
| FY2022 | Dec 31, 2022 | 57.3% | −172.1 |
| FY2021 | Dec 31, 2021 | 229.4% | +196.3 |
| FY2020 | Dec 31, 2020 | 33.1% | −1.3 |
| FY2019 | Dec 31, 2019 | 34.4% | −19.0 |
| FY2018 | Dec 31, 2018 | 53.4% | −0.3 |
| FY2017 | Dec 31, 2017 | 53.7% | +4.5 |
| FY2016 | Dec 31, 2016 | 49.2% | +22.5 |
| FY2015 | Dec 31, 2015 | 26.7% | +12.8 |
| FY2014 | Dec 31, 2014 | 14.0% | −2.1 |
| FY2013 | Dec 31, 2013 | 16.0% | −5.1 |
| FY2012 | Dec 31, 2012 | 21.2% | +0.5 |
| FY2011 | Dec 31, 2011 | 20.6% | +0.9 |
| FY2010 | Dec 31, 2010 | 19.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 61.9% | +4.8 |
| Q1 FY2026 | Mar 31, 2026 | 65.4% | +1.4 |
| Q4 FY2025 | Dec 31, 2025 | 65.5% | +1.8 |
| Q3 FY2025 | Sep 30, 2025 | 62.1% | −2.2 |
| Q2 FY2025 | Jun 30, 2025 | 57.1% | −7.7 |
| Q1 FY2025 | Mar 31, 2025 | 64.0% | +2.0 |
| Q4 FY2024 | Dec 31, 2024 | 63.7% | +1.4 |
| Q3 FY2024 | Sep 30, 2024 | 64.3% | +5.8 |
| Q2 FY2024 | Jun 30, 2024 | 64.8% | −0.5 |
| Q1 FY2024 | Mar 31, 2024 | 62.0% | −1.6 |
| Q4 FY2023 | Dec 31, 2023 | 62.3% | +43.2 |
| Q3 FY2023 | Sep 30, 2023 | 58.5% | −315.0 |
| Q2 FY2023 | Jun 30, 2023 | 65.4% | −130.4 |
| Q1 FY2023 | Mar 31, 2023 | 63.6% | −126.2 |
| Q4 FY2022 | Dec 31, 2022 | 19.2% | −9.7 |
| Q3 FY2022 | Sep 30, 2022 | 373.5% | +318.4 |
| Q2 FY2022 | Jun 30, 2022 | 195.8% | +147.8 |
| Q1 FY2022 | Mar 31, 2022 | 189.8% | +143.9 |
| Q4 FY2021 | Dec 31, 2021 | 28.9% | −3.5 |
| Q3 FY2021 | Sep 30, 2021 | 55.1% | +18.0 |
| Q2 FY2021 | Jun 30, 2021 | 48.0% | +18.7 |
| Q1 FY2021 | Mar 31, 2021 | 45.9% | +13.4 |
| Q4 FY2020 | Dec 31, 2020 | 32.4% | +60.5 |
| Q3 FY2020 | Sep 30, 2020 | 37.0% | −0.4 |
| Q2 FY2020 | Jun 30, 2020 | 29.3% | −22.4 |
| Q1 FY2020 | Mar 31, 2020 | 32.5% | −23.9 |
| Q4 FY2019 | Dec 31, 2019 | -28.1% | −83.4 |
| Q3 FY2019 | Sep 30, 2019 | 37.4% | −14.6 |
| Q2 FY2019 | Jun 30, 2019 | 51.7% | −7.5 |
| Q1 FY2019 | Mar 31, 2019 | 56.4% | +10.0 |
| Q4 FY2018 | Dec 31, 2018 | 55.3% | −7.2 |
| Q3 FY2018 | Sep 30, 2018 | 52.0% | +1.2 |
| Q2 FY2018 | Jun 30, 2018 | 59.2% | +7.9 |
| Q1 FY2018 | Mar 31, 2018 | 46.4% | −2.6 |
| Q4 FY2017 | Dec 31, 2017 | 62.5% | +19.3 |
| Q3 FY2017 | Sep 30, 2017 | 50.8% | +6.4 |
| Q2 FY2017 | Jun 30, 2017 | 51.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 49.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 43.1% | – |
| Q3 FY2016 | Sep 30, 2016 | 44.3% | – |
See a number that looks wrong?